With the progression of NAFLD, the Lpl/Fabp4/Cpt1 molecule axis and controlled fatty acid metabolism were generally upregulated since the NASH phase (Yang et al., 2021). The gene discussed is FABP4; the disease is metabolic dysfunction-associated steatohepatitis.